Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Status:
Withdrawn
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is
advantageous for advanced esophageal cancer patients in combination with chemotherapy or
radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to
advanced esophageal cancer patients is not known.